Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias

Mendes, Aline; Bertrand, Anne; Lamari, Foudil; Colliot, Olivier; Routier, Alexandre; Godefroy, Olivier; Etcharry-Bouyx, Frédérique; Moreaud, Olivier; Pasquier, Florence; Couratier, Philippe; Bennys, Karim; Vercelletto, Martine; Martinaud, Olivier; Laurent, Bernard; Pariente, Jérémie; Puel, Michèle; Epelbaum, Stéphane; Belliard, Serge; Kaaouana, Takoua; Fillon, Ludovic; Chupin, Marie; Dubois, Bruno; Teichmann, Marc

doi:10.1212/wnl.0000000000005165

Cited by 13 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following initial observations by Caroppo et al [23], she showed, in a study with her medical student Fatima Ameur, that atypical white matter abnormalities are common in patients with progranulin mutation but not in those with c9orf72 mutation, suggesting a specific vulnerability of the white matter to granulin haploinsufficiency [24]. She was also interested in primary progressive aphasias [25][26][27]. In collaboration with Dr Marc Teichmann, she studied the prevalence and localization of cerebral microbleeds (CMB) in the three main variants of primary progressive aphasia, demonstrating that CBM are most prevalent in the logopenic variant and related to an underlying Alzheimer's pathology and do not affect language/cognitive impairment [26].…”

Section: Main Scientific Contributions Mri In Acute Strokementioning

confidence: 99%

“…She was also interested in primary progressive aphasias [25][26][27]. In collaboration with Dr Marc Teichmann, she studied the prevalence and localization of cerebral microbleeds (CMB) in the three main variants of primary progressive aphasia, demonstrating that CBM are most prevalent in the logopenic variant and related to an underlying Alzheimer's pathology and do not affect language/cognitive impairment [26].…”

Section: Main Scientific Contributions Mri In Acute Strokementioning

confidence: 99%

See 1 more Smart Citation

Tribute to Anne Bertrand (1978–2018): Neuroradiologist, scientist, teacher and friend

Dormont

Ben‐Eliezer

Burgos

et al. 2019

Journal of Neuroradiology

Self Cite

View full text Add to dashboard Cite

Anne Bertrand passed away on March 2nd 2018. She was in a touring-skiers group led by a guide and swept by an avalanche in the French Alps. This paper is a tribute to Anne and an attempt, by some of her closest colleagues, to provide an overview of her major contributions. Anne Bertrand was a rising star of the neuroimaging community who traced innovative paths at the interface of basic science and clinical neuroradiology. From the very beginning of her career, she had been interested in the cross-fertilization between research and medical practice. After an MD and a specialization in neuroradiology, she prepared a PhD in preclinical imaging at the French Atomic Energy Commission (CEA) and at New York University. She was then appointed as Senior Neuroradiologist (at the Pitié-Salpêtrière and then Saint-Antoine Hospital in Paris) and Associate Professor (Sorbonne University). Simultaneously, she continued to develop her research activities in the ARAMIS Laboratory at the Brain and Spinal Cord Institute (ICM). Her main field of interest was neuroimaging of dementias. In a short time, she made important and exceptionally diverse contributions to the understanding, detection, diagnosis and tracking of these disorders (including Alzheimer's disease and fronto-temporal lobar degeneration) using advanced multimodal neuroimaging techniques. They will be a source of inspiration for all of us. Anne was not only an outstandingly bright scientist but also enlightening by her personal qualities: joy, openness, kindness and generosity.

show abstract

Section: Main Scientific Contributions Mri In Acute Strokementioning

confidence: 99%

Section: Main Scientific Contributions Mri In Acute Strokementioning

confidence: 99%

Tribute to Anne Bertrand (1978–2018): Neuroradiologist, scientist, teacher and friend

Dormont

Ben‐Eliezer

Burgos

et al. 2019

Journal of Neuroradiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, one multicenter cohort study with CSF analysis revealed that CMBs were more frequent in patients with AD pathology than without AD pathology (65) and another study with Aβ PET showed that parietal CMBs were associated with cerebral Aβ burden (66). Although these findings suggest that cerebral SVD may play a significant role in AD development, there is still a possibility that cerebral Aβ deposition will cause white matter alteration (67)(68)(69), due to the limitations of the cross-sectional study design.…”

Section: Relationship Between Ad Biomarkers and Cerebral Svdmentioning

confidence: 99%

Cerebral Small Vessel Disease and Alzheimer's Disease: A Review

2020

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most common cause of dementia. Despite this, clear pathophysiology for AD has not been confirmed, and effective treatments are still not available. As AD results in a complex disease process for cognitive decline, various theories have been suggested as the cause of AD. Recently, cerebral small vessel disease (SVD) has been suggested to contribute to the pathogenesis of AD, as well as contributing to vascular dementia. Cerebral SVD refers to a varied group of diseases that affect cerebral small arteries and microvessels. These can be seen as white matter hyperintensities, cerebral microbleeds, and lacunes on magnetic resonance imaging. Data from epidemiological and clinical-pathological studies have found evidence of the relationship between cerebral SVD and AD. This review aims to discuss the complex relationship between cerebral SVD and AD. Recent reports that evaluate the association between these diseases will be reviewed.

show abstract

“…Mendes et al identified focal microhemorrhages in their cohort of FTD patients with unique focal prevalence for each sub-diagnosis. 12 As shown in patients with multiple sclerosis, T1 and T2 relaxometry, or mapping, detect structural tissue changes very sensitively at very early stages of the disease. These findings make frontotemporal spectrum dementias suitable for T1-and T2-relaxometric mapping analyses.…”

Section: Introductionmentioning

confidence: 99%

“…Changes in neuronal connectivity observed by DTI stresses the involvement of white matter structures. Mendes et al identified focal microhemorrhages in their cohort of FTD patients with unique focal prevalence for each sub‐diagnosis 12 …”

Section: Introductionmentioning

confidence: 99%

MR fingerprinting as a diagnostic tool in patients with frontotemporal lobe degeneration: A pilot study

et al. 2019

View full text Add to dashboard Cite

Several very rare forms of dementia are associated with characteristic focal atrophy predominantly of the frontal and/or temporal lobes and currently lack imaging solutions to monitor disease. Magnetic resonance fingerprinting (MRF) is a recently developed technique providing quantitative relaxivity maps and images with various tissue contrasts out of a single sequence acquisition. This pilot study explores the utility of MRF‐based T1 and T2 mapping to discover focal differences in relaxation times between patients with frontotemporal lobe degenerative dementia and healthy controls. 8 patients and 30 healthy controls underwent a 3 T MRI including an axial 2D spoiled gradient echo MRF sequence. T1 and T2 relaxation maps were generated based on an extended phase graphs algorithm‐founded dictionary involving inner product pattern matching. A region of interest (ROI)‐based analysis of T1 and T2 relaxation times was performed with FSL and ITK‐SNAP. Depending on the brain region analyzed, T1 relaxation times were up to 10.28% longer in patients than in controls reaching significant differences in cortical gray matter (P = .047) and global white matter (P = .023) as well as in both hippocampi (P = .001 left; P = .027 right). T2 relaxation times were similarly longer in the hippocampus by up to 19.18% in patients compared with controls. The clinically most affected patient had the most control‐deviant relaxation times. There was a strong correlation of T1 relaxation time in the amygdala with duration of the clinically manifest disease (Spearman Rho = .94; P = .001) and of T1 relaxation times in the left hippocampus with disease severity (Rho = .90, P = .002). In conclusion, MRF‐based relaxometry is a promising and time‐saving new MRI tool to study focal cerebral alterations and identify patients with frontotemporal lobe degeneration. To validate the results of this pilot study, MRF is worth further exploration as a diagnostic tool in neurodegenerative diseases.

show abstract

Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias

Cited by 13 publications

References 32 publications

Tribute to Anne Bertrand (1978–2018): Neuroradiologist, scientist, teacher and friend

Tribute to Anne Bertrand (1978–2018): Neuroradiologist, scientist, teacher and friend

Cerebral Small Vessel Disease and Alzheimer's Disease: A Review

MR fingerprinting as a diagnostic tool in patients with frontotemporal lobe degeneration: A pilot study

Contact Info

Product

Resources

About